Chinese regulators crack down on counterfeiters; BASi reports 14% revenue drop in Q3;

> Chinese regulators are sick of counterfeit drugs and devices getting into the company's market, so the government is publishing a blacklist of manufacturers and suppliers who have run afoul of Chinese law. Item

> BASi ($BASi) saw its revenue drop 14% to $7.2 million in the third quarter, but the company is optimistic about its future growth. News

> WuXi PharmaTech's Suzhou facility received GLP certification from China's State Food and Drug Administration, allowing the company to perform non-clinical lab studies there. Article

> IMS Health has purchased TTC, an outfit that specializes in calculating cost and negotiating prices for clinical trials. The company didn't disclose an acquisition price. More

> The FDA has updated its guidance on suicide risk in clinical trials, responding to increasing reports of certain populations taking antidepressants and antiepileptics. Story

> DaVita is opening a Colorado Phase I facility to focus on kidney research, targeting drugmakers seeking renal trials. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.